[go: up one dir, main page]

GT200600315A - Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida - Google Patents

Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida

Info

Publication number
GT200600315A
GT200600315A GT200600315A GT200600315A GT200600315A GT 200600315 A GT200600315 A GT 200600315A GT 200600315 A GT200600315 A GT 200600315A GT 200600315 A GT200600315 A GT 200600315A GT 200600315 A GT200600315 A GT 200600315A
Authority
GT
Guatemala
Prior art keywords
ilo
methyl
iloamino
pirimidina
trifluorometilo
Prior art date
Application number
GT200600315A
Other languages
English (en)
Inventor
Paul W Manley
Wen-Chung Shieh
Paul Allen Sutton
Piotr H Karpinski
Raeann Wu
Stephanie Monnier
Joerg Brozio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600315(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600315A publication Critical patent/GT200600315A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A FORMAS CRISTALINAS DE 4-METILO-N-[3-(4-METILO-IMIDAZOL-1-ILO)-5-TRIFLUOROMETILO-FENILO]-3-(4-PYRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO)-BENZAMIDA DE BASE LIBRE, SUS SALES PREPARADAS POR VARIOS PROCESOS.
GT200600315A 2005-07-20 2006-07-14 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida GT200600315A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70140505P 2005-07-20 2005-07-20
US71621405P 2005-09-12 2005-09-12

Publications (1)

Publication Number Publication Date
GT200600315A true GT200600315A (es) 2007-03-19

Family

ID=37451227

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600315A GT200600315A (es) 2005-07-20 2006-07-14 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida

Country Status (43)

Country Link
US (4) US8343984B2 (es)
EP (5) EP2543665A3 (es)
JP (3) JP5289948B2 (es)
KR (3) KR20130085444A (es)
CN (2) CN102358736A (es)
AR (1) AR054846A1 (es)
AU (3) AU2006276204A1 (es)
BR (1) BRPI0613615B1 (es)
CA (1) CA2614334C (es)
CR (1) CR9657A (es)
CU (1) CU23916B1 (es)
CY (2) CY1113076T1 (es)
DK (2) DK1912973T3 (es)
EA (2) EA013464B1 (es)
EC (1) ECSP088119A (es)
ES (3) ES2623608T5 (es)
GE (1) GEP20115302B (es)
GT (1) GT200600315A (es)
HK (1) HK1116783A1 (es)
HN (1) HN2008000311A (es)
HR (2) HRP20120573T1 (es)
HU (1) HUE031791T2 (es)
IL (2) IL188189A0 (es)
JO (1) JO3308B1 (es)
LT (1) LT2284167T (es)
MA (1) MA29626B1 (es)
MX (1) MX2008000899A (es)
MY (1) MY148554A (es)
NI (1) NI200800017A (es)
NO (1) NO341930B1 (es)
NZ (1) NZ564409A (es)
PE (1) PE20070214A1 (es)
PH (1) PH12013501590A1 (es)
PL (2) PL2284167T5 (es)
PT (2) PT2284167T (es)
RS (1) RS55929B2 (es)
SG (1) SG163620A1 (es)
SI (2) SI2284167T2 (es)
SM (1) SMP200800011B (es)
TN (1) TNSN08029A1 (es)
TW (1) TWI406661B (es)
UA (1) UA94234C2 (es)
WO (1) WO2007015870A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
KR101292508B1 (ko) * 2006-04-07 2013-08-01 노파르티스 아게 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2009082662A1 (en) 2007-12-21 2009-07-02 Novartis Ag Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia
US20100016590A1 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
KR101251726B1 (ko) 2008-11-05 2013-04-05 테바 파마슈티컬 인더스트리즈 리미티드 닐로티닙 ＨＣｌ 결정형
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
KR20110132439A (ko) 2009-03-06 2011-12-07 노파르티스 아게 류신 지퍼- 및 스테릴 알파 모티프-함유 키나제 （ｚａｋ）에 의해 매개된 장애의 치료를 위한 피리미딜아미노벤즈아미드 유도체의 용도
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
CN102647986A (zh) 2009-10-23 2012-08-22 诺瓦提斯公司 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2011086541A1 (en) * 2010-01-15 2011-07-21 Generics [Uk] Limited Novel polymorph of nilotinib monohydrochloride monohydrate
EP2558098A2 (en) 2010-04-16 2013-02-20 Novartis AG Treatment of endocrine resistant breast cancer
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
KR20130042498A (ko) 2010-06-21 2013-04-26 테바 파마슈티컬 인더스트리즈 리미티드 닐로티닙 염 및 이의 결정형
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
EP2648519A4 (en) * 2010-11-26 2014-04-30 Hetero Research Foundation NEW POLYMORPH OF NILOTINIB HYDROCHLORIDE
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
PH12014500897A1 (en) 2011-10-28 2019-10-07 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
MX2014005874A (es) 2011-11-14 2014-06-23 Novartis Ag Formulacion de liberacion inmediata de 4 - metil - 3 - [ [4- (3-piridinil) - 2 - pirimidinil] - amino] - n - [5 - (4 - metil - 1h - imidazol - 1 - il) - 3 - (trifluoro-metil) - fenil] - benzamida.
ES2564969T3 (es) * 2012-02-09 2016-03-30 Natco Pharma Limited Proceso para la preparación de clorhidrato de nilotinib
GB2514285B (en) 2012-02-13 2018-07-18 Grindeks Jsc Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
JP2015522070A (ja) 2012-07-11 2015-08-03 ノバルティス アーゲー 消化管間質腫瘍を治療する方法
WO2014059518A1 (en) * 2012-10-15 2014-04-24 Apotex Technologies Inc. Solid forms of nilotinib hydrochloride
RU2652121C2 (ru) * 2012-10-19 2018-04-25 Басф Се Многокомпонентная кристаллическая система, содержащая нилотиниб и выбранные сокристаллообразователи
WO2014128588A1 (en) * 2013-02-21 2014-08-28 Pfizer Inc. Solid forms of a selective cdk4/6 inhibitor
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
EA201592032A1 (ru) 2013-04-24 2016-04-29 Др. Реддис Лабораторис Лимитед Полиморфные формы гидрохлорида нилотиниба
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
EP3177610A4 (en) 2014-08-08 2018-01-10 Dr. Reddy's Laboratories Ltd. Process for the preparation of polymorphic forms of nilotinib
US10016423B2 (en) * 2014-10-16 2018-07-10 Apotex Inc. Solid forms of nilotinib hydrochloride
EP3408264B1 (en) 2016-01-26 2020-03-11 Farma GRS, d.o.o. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
US10640487B2 (en) 2016-03-14 2020-05-05 Teva Pharmaceuticals Usa, Inc. Solid state forms of Nilotinib salts
CN106496193A (zh) * 2016-09-13 2017-03-15 福格森（武汉）生物科技股份有限公司 一种高纯度尼罗替尼的制备方法
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法
EP3877379A4 (en) * 2018-11-05 2022-08-31 Laurus Labs Limited CRYSTALLINE FORM OF NILOTINIB HYDROCHLORIDE, METHOD FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION CONTAINING IT
AU2021212258A1 (en) 2020-01-31 2022-09-29 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
JP2023543815A (ja) 2020-09-29 2023-10-18 シェンチェン ファーマシン シーオー．，エルティーディー． 医薬組成物
AU2022292092A1 (en) 2021-06-19 2024-02-01 Helm Ag Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701406A (en) 1901-07-16 1902-06-03 Thomas K Jones Cut-off-valve mechanism.
US701405A (en) 1902-02-17 1902-06-03 Archibald White Maconochie Ejecting device for stamping-machines.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
MXPA06005598A (es) * 2003-11-18 2006-08-11 Novartis Ag Inhibidores de la forma mutante de kit.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) † 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Also Published As

Publication number Publication date
EP2543665A2 (en) 2013-01-09
AU2012201453C1 (en) 2024-05-23
CN103804356A (zh) 2014-05-21
EP2284167B2 (en) 2019-11-27
JP2013018789A (ja) 2013-01-31
PT1912973E (pt) 2012-09-03
EP2284167B1 (en) 2017-02-01
CA2614334C (en) 2015-04-21
SMAP200800011A (it) 2008-02-27
DK1912973T3 (da) 2012-07-23
AU2012201453A1 (en) 2012-04-05
GEP20115302B (en) 2011-10-10
SI2284167T2 (sl) 2020-03-31
KR101651288B1 (ko) 2016-08-25
CN102358736A (zh) 2012-02-22
MX2008000899A (es) 2008-03-18
HK1116783A1 (es) 2009-01-02
US20130023548A1 (en) 2013-01-24
US8829015B2 (en) 2014-09-09
EA201000145A1 (ru) 2010-06-30
CA2614334A1 (en) 2007-02-08
EP2284167A2 (en) 2011-02-16
ES2648288T3 (es) 2017-12-29
SI1912973T1 (sl) 2012-08-31
HN2008000311A (es) 2011-01-24
AU2012201453B2 (en) 2013-09-05
PL2284167T5 (pl) 2020-07-27
NO20080820L (no) 2008-04-15
EA013464B1 (ru) 2010-04-30
CU20080006A7 (es) 2011-02-24
AU2006276204A1 (en) 2007-02-08
TNSN08029A1 (en) 2009-07-14
HRP20120573T1 (hr) 2012-08-31
CU23916B1 (es) 2013-07-31
ECSP088119A (es) 2008-02-20
BRPI0613615A2 (pt) 2011-01-18
ES2386974T3 (es) 2012-09-10
PH12013501590A1 (en) 2015-09-21
KR20130085444A (ko) 2013-07-29
PL2284167T3 (pl) 2017-07-31
DK2284167T3 (en) 2017-05-01
DK2284167T4 (da) 2020-03-02
RS55929B2 (sr) 2020-12-31
EP2284168A3 (en) 2011-04-13
HUE031791T2 (en) 2017-08-28
JP2009502795A (ja) 2009-01-29
HRP20170634T4 (hr) 2020-02-07
EP2535337A1 (en) 2012-12-19
ES2623608T5 (es) 2020-06-18
JP2014221831A (ja) 2014-11-27
CY1119624T1 (el) 2018-04-04
TWI406661B (zh) 2013-09-01
US8343984B2 (en) 2013-01-01
PT2284167T (pt) 2017-05-15
AU2011202047A1 (en) 2011-05-26
IL214659A0 (en) 2011-09-27
CY1113076T1 (el) 2016-04-13
EP2284168A2 (en) 2011-02-16
WO2007015870A2 (en) 2007-02-08
JP5798101B2 (ja) 2015-10-21
MA29626B1 (fr) 2008-07-01
NO341930B1 (no) 2018-02-19
EP2535337B1 (en) 2017-08-23
CR9657A (es) 2008-04-16
KR20080027853A (ko) 2008-03-28
MY148554A (en) 2013-04-30
US20130165465A1 (en) 2013-06-27
US20140343087A1 (en) 2014-11-20
HRP20170634T1 (hr) 2017-06-30
SI2284167T1 (sl) 2017-05-31
WO2007015870A3 (en) 2007-06-07
EA016856B1 (ru) 2012-08-30
US8415363B2 (en) 2013-04-09
JP5289948B2 (ja) 2013-09-11
EP1912973A2 (en) 2008-04-23
JO3308B1 (ar) 2018-09-16
AR054846A1 (es) 2007-07-18
EP2543665A3 (en) 2013-05-29
US20080269269A1 (en) 2008-10-30
IL188189A0 (en) 2008-03-20
NZ564409A (en) 2011-07-29
BRPI0613615B1 (pt) 2022-02-08
PL1912973T3 (pl) 2012-09-28
KR20130077915A (ko) 2013-07-09
LT2284167T (lt) 2017-04-25
EA200800201A1 (ru) 2008-06-30
ES2623608T3 (es) 2017-07-11
SMP200800011B (it) 2008-02-27
TW200740793A (en) 2007-11-01
EP2284167A3 (en) 2011-03-02
UA94234C2 (uk) 2011-04-26
SG163620A1 (en) 2010-08-30
PE20070214A1 (es) 2007-04-02
RS55929B1 (sr) 2017-09-29
NI200800017A (es) 2009-03-03
EP1912973B1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
GT200600315A (es) Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
UY29683A1 (es) Sales de 4-metil-n-(3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil)-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
HN2007000536A (es) Formas cristalinas
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
AR085903A1 (es) Compuestos de pirazol sustituidos con halogeno
CY1112511T1 (el) Κρυσταλλικη στερεα βαση ρασαγιλινης (rasagiline)
TW200716512A (en) Processes for preparing cinacalcet hydrochloride crystal form I
UY30639A1 (es) Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
EP1733480A4 (en) PERIODIC CALIBRATION FOR COMMUNICATION CHANNELS BY REFERRING UNDESIRABLE VARIATIONS
EA200801959A1 (ru) Высокоразветвленный полипропилен
CR9866A (es) Novedosos derivados de 1-aza-bicicloalquilo para el tratamiento de trastornos psicoticos y neurodegenerativos
MA31985B1 (fr) (r)-2-(4-cyclopropanesulfonyl-phényl)-n-pyrazin-2-yl-3-(tétrahydropyran-4-yl)- propionamide cristallin
DE502005007669D1 (de) Aktuierungsmittel für eine crash-aktive kopfstütze
RS52255B (en) NALMEFEN HYDROCHLORIDE DIHYDRATE
HN2009001436A (es) Nuevo procedimiento de sintesis de la agometatina
TW200640886A (en) Crystalline forms of linezolid intermediate
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina
HN2011000745A (es) Sales de n-[6-cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4´-(triflouro-metoxi)-[1,1´-bifenil]-3-carboxamida
CY1116596T1 (el) Αλατα ισοφωσφοραμιδικης μουσταρδας και αναλογα αυτων
ECSP11011167A (es) Síntesis y formas de sales novedosas de (r) -5- ( (e) -2- (pirrolidin-3-ilvinil) pirimidina
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
CY1109038T1 (el) Μη στεροειδεις ρυθμιστες υποδοχεα γλυκοκορτικοειδων
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
EP2183256A4 (en) THERAPEUTIC COMPOUNDS
PA8645401A1 (es) Procedimiento de fabricacion de compuestos imidazolicos, sus sales y sus pseudopolimorfos